FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to polypeptides for reducing the risk and for delaying the onset of multiple myeloma in a subject. Also disclosed are polynucleotides coding said polypeptides, an expression vector, pharmaceutical compositions for reducing the risk and for delaying the onset of multiple myeloma in a subject. Invention also relates to a method of inducing an immune response against multiple myeloma in a subject.
EFFECT: invention enables to induce an immune response against multiple myeloma in a subject.
35 cl, 9 dwg, 12 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AFRICAN SWINE FEVER VACCINE | 2020 |
|
RU2819672C2 |
| VIRAL VECTORS ENCODING RECOMBINANT FIX VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA B | 2018 |
|
RU2773956C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| NEW VERSION OF MDTH AND METHOD OF PRODUCING O-PHOSPHOSERINE, CYSTEINE AND CYSTEINE DERIVATIVE USING SAME | 2021 |
|
RU2835524C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| MICROORGANISM PRODUCING LYSINE AND A METHOD OF PRODUCING LYSINE | 2021 |
|
RU2797843C9 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| COMBINED MEDICINAL PRODUCTS TARGETING PD-1, TIM-3 AND LAG-3 | 2018 |
|
RU2795232C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
